CL2009000190A1 - Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden. - Google Patents

Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.

Info

Publication number
CL2009000190A1
CL2009000190A1 CL2009000190A CL2009000190A CL2009000190A1 CL 2009000190 A1 CL2009000190 A1 CL 2009000190A1 CL 2009000190 A CL2009000190 A CL 2009000190A CL 2009000190 A CL2009000190 A CL 2009000190A CL 2009000190 A1 CL2009000190 A1 CL 2009000190A1
Authority
CL
Chile
Prior art keywords
virus
genome
antigenome
nucleocapsid
bird
Prior art date
Application number
CL2009000190A
Other languages
English (en)
Inventor
Rudolf Beier Dr
Florian Puhler Dr
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CL2009000190A1 publication Critical patent/CL2009000190A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molécula de ADN que codifica el genoma y/o antigenoma del virus; célula y composición que lo comprenden.
CL2009000190A 2008-01-29 2009-01-29 Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden. CL2009000190A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2433308P 2008-01-29 2008-01-29
EP08001643A EP2085092A1 (en) 2008-01-29 2008-01-29 Attenuated oncolytic paramyxoviruses encoding avian cytokines

Publications (1)

Publication Number Publication Date
CL2009000190A1 true CL2009000190A1 (es) 2010-07-19

Family

ID=39708421

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000190A CL2009000190A1 (es) 2008-01-29 2009-01-29 Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.

Country Status (22)

Country Link
US (1) US20100092430A1 (es)
EP (2) EP2085092A1 (es)
JP (1) JP2011510638A (es)
KR (1) KR20100113096A (es)
CN (1) CN102099045A (es)
AR (1) AR070272A1 (es)
AU (1) AU2009210301A1 (es)
BR (1) BRPI0906354A2 (es)
CA (1) CA2711571A1 (es)
CL (1) CL2009000190A1 (es)
CO (1) CO6290693A2 (es)
CR (1) CR11616A (es)
DO (1) DOP2010000233A (es)
EA (1) EA201001202A1 (es)
EC (1) ECSP10010375A (es)
IL (1) IL206382A0 (es)
MX (1) MX2010008370A (es)
PA (1) PA8813901A1 (es)
PE (1) PE20091355A1 (es)
TW (1) TW200936159A (es)
WO (1) WO2009095167A1 (es)
ZA (1) ZA201006151B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
EP2987856B1 (en) 2009-02-05 2018-07-25 Icahn School of Medicine at Mount Sinai Chimeric newcastle disease viruses and uses thereof
US9937196B2 (en) * 2009-06-19 2018-04-10 University Of Maryland, College Park Genomic sequence of avian paramyxovirus type 2 and uses thereof
EP2739293B1 (en) 2011-08-05 2020-06-10 SillaJen Biotherapeutics, Inc. Methods and compositions for production of vaccina virus
EP2968525A4 (en) 2013-03-14 2016-10-26 Icahn School Med Mount Sinai MORBUS NEWCASTLE VIRUSES AND USES THEREOF
HUE042382T2 (hu) 2013-09-03 2019-06-28 Medimmune Ltd Legyengített Newcastle betegség vírust tartalmazó készítmények és azok alkalmazása neoplázia kezelési eljárásában történõ alkalmazásra
EP3110443A4 (en) 2014-02-27 2017-11-15 Viralytics Limited Combination method for treatment of cancer
GB201505860D0 (en) * 2015-04-07 2015-05-20 Agalimmune Ltd Therapeutic compositions and methods of use for treating cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
CN108362875A (zh) * 2018-01-10 2018-08-03 华南农业大学 一种鉴别新城疫感染与免疫的间接elisa方法
CN111094324B (zh) * 2018-03-14 2023-10-10 武汉博威德生物技术有限公司 一种溶瘤病毒、合成dna序列及其应用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
TWI894135B (zh) 2019-01-25 2025-08-21 德商百靈佳殷格翰國際股份有限公司 編碼ccl21之重組棒狀病毒
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE257175T1 (de) 1994-07-18 2004-01-15 Conzelmann Karl Klaus Prof Dr Rekombinantes infektiöses nicht-in-segmente- geteiltes, negativ-strange-rns-virus
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2312626A1 (en) 1999-07-27 2001-01-27 Akzo Nobel N.V. A recombinant newcastle disease virus as an embryo vaccine
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ATE451835T1 (de) 1999-09-24 2010-01-15 Mayo Foundation Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ES2278810T3 (es) 2000-11-02 2007-08-16 Intervet International Bv Nucleoproteina recombinante mutante del virus de la enfermedad de newcastle (ndv) como marcador de vacuna.
CA2452517A1 (en) 2001-07-11 2003-01-23 University Of Miami Recombinant vsv for the treatment of tumor cells
ATE307606T1 (de) 2001-10-04 2005-11-15 Ct Voor Onderzoek In Diergenee Abgeschwächter mutantenstamm eines virus der newcastle-krankheit für eine in ovo impfung und dessen benutzung
US20040072276A1 (en) 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
AU2004249904A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株

Also Published As

Publication number Publication date
CN102099045A (zh) 2011-06-15
US20100092430A1 (en) 2010-04-15
CR11616A (es) 2010-09-09
ECSP10010375A (es) 2010-08-31
TW200936159A (en) 2009-09-01
KR20100113096A (ko) 2010-10-20
CO6290693A2 (es) 2011-06-20
EA201001202A1 (ru) 2011-02-28
JP2011510638A (ja) 2011-04-07
EP2237790A1 (en) 2010-10-13
BRPI0906354A2 (pt) 2019-12-17
CA2711571A1 (en) 2009-08-06
ZA201006151B (en) 2012-02-29
PE20091355A1 (es) 2009-10-04
DOP2010000233A (es) 2010-08-15
MX2010008370A (es) 2010-08-23
IL206382A0 (en) 2010-12-30
AU2009210301A1 (en) 2009-08-06
WO2009095167A1 (en) 2009-08-06
EP2085092A1 (en) 2009-08-05
PA8813901A1 (es) 2009-08-26
AR070272A1 (es) 2010-03-25

Similar Documents

Publication Publication Date Title
CL2009000190A1 (es) Virus recombinante de la enfermedad de newcastle que comprende un transgen que codifica una citoquina de ave; nucleocapside y genoma de dicho virus; molecula de adn que codifica el genoma y/o antigenoma del virus; celula y composicion que lo comprenden.
ES2566033T3 (es) Parvovirus recombinante atenuado
CO6511253A2 (es) Vacuna de paramixovirus aviar recombinante y metodo para producri y usar la misma
CY1114736T1 (el) Προερχομενες απο παπια εμβρυϊκες βλαστικες κυτταρικες σειρες για την παραγωγη ιικων εμβολιων
EP4659816A3 (en) MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
DE602008002693D1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
CY1118136T1 (el) Αναστολεις πρωτεασης hcv
UY33311A (es) Fosforamidatos de nucleosidos
EA201000948A1 (ru) Ингибиторы вирусной полимеразы
PT2285408T (pt) Sequências de aminoácidos dirigidas contra proteínas de envelope de um vírus e polipéptidos que as compreendem para o tratamento de doenças virais
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
DK2190473T3 (da) Peptid med reduceret dimerdannelse
CL2009000305A1 (es) Compuestos derivados de 2-aril-sustituido-1-benzofurano-3-carboxamida, inhibidores de la polimerasa ns5b; composicion farmaceutica; y su uso en el tratamiento de una enfermedad causada por el virus de la hepatitis c (hcv).
EA201001045A1 (ru) Модифицированный вирус гриппа
CR20110605A (es) Compuestos heterocíclicos antivirales
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
IL212787A0 (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2011072247A3 (en) Pathogen restriction factors
CO6362047A2 (es) Virus sincitial respiratorio vivo atenuado
BRPI0721984B8 (pt) interferon-2b peguilado (ifn-2b), seu método de preparo e de purificação, composição, bem como uso dos mesmos
AR117877A1 (es) Rhabdovirus recombinante que codifica ccl21
CL2008003821A1 (es) Metodo para producir el virus de la estomatitis vesicular (vsv) atenuado en celulas, que comprende: a) proporcionar una celula que comprende un gen g vsv optimizado e inducible, b) inducir la celula a expresar dicho gen, c) infectar la celula con un vsv atenuado, d) hacer crecer dichas celulas, y e) recuperar el vsv atenuado
CU24060B1 (es) Composición vacunal contra el virus del dengue, kit y plásmido
CO6290645A2 (es) Compuesto para el tratamiento de la hepatitis c